{
    "clinical_study": {
        "@rank": "4853", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multicenter observational study will evaluate the efficacy and safety of Mircera\n      (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease not on\n      dialysis in routine clinical practice. Eligible patients treated with Mircera for chronic\n      renal anemia according to the standard of care and in line with the current local label will\n      be followed for 6 months."
        }, 
        "brief_title": "A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis", 
        "completion_date": {
            "#text": "February 2011", 
            "@type": "Anticipated"
        }, 
        "condition": "Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, 18 to 65 years of age inclusive\n\n          -  Patients with chronic kidney disease Stage III-IV not on dialysis\n\n          -  Hb < 10 g/dL (for correction of anemia) or Hb 10-12 g/dL and receiving any other ESA\n             (for maintenance of Hb levels)\n\n          -  Adequate iron status as judged by the treating physician\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any\n             constituent of the study medication\n\n          -  Significant acute or chronic bleeding\n\n          -  Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)\n\n          -  Active malignant disease during the last five years (except non-melanoma skin cancer)\n\n          -  Uncontrolled or symptomatic secondary hyperparathyroidism\n\n          -  Epileptic seizure during the last 6 months\n\n          -  Poorly controlled hypertension (sitting blood pressure > 170/100 mmHG)\n\n          -  Myocardial infarction or stroke, or severe or unstable CAD\n\n          -  Severe liver disease during the previous 6 months\n\n          -  Congestive heart failure NYHA Class III-IV\n\n          -  Diagnosis or suspicion of pure red cell aplasia (PRCA)\n\n          -  Planned elective surgery during the study period (except cataract surgery and\n             vascular access surgery)\n\n          -  Transfusion of red blood cells during the previous 2 months\n\n          -  Pregnant women\n\n          -  Any contra-indications to Mircera"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic kidney disease not on dialysis receiving treatment with Mircera for\n        chronic renal anemia"
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892202", 
            "org_study_id": "ML25750"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "number_of_groups": "1", 
        "official_title": "Efficacy of C.E.R.A for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients in Stage III - IV , Not on Dialysis , Treated According to Routine Clinical Practice", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Bangladesh: Director General of Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2011", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Mean time required to achieve target Hb range (10-12 g/dL)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Percentage of patients maintaining Hb level within 1 g/dL of baseline value during study period in patients who have received treatment with other ESAs", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892202"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients achieving target Hb range at least once during study", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Mean time spent in the target Hb range", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014", 
        "why_stopped": "Investigators lost interest in conducting the trail due to unexplained reasons"
    }
}